To the Editor.—
Intralesional interferon alfa-2b (Schering Corp, Kenilworth, NJ) has generated significant clinical interest for its potential use in the treatment of a variety of benign and malignant skin tumors. The acute side effects of the interferons are well described and are usually transient.1 We report two unusual malignant cutaneous tumors (dermatofibrosarcoma protuberans of the scalp and sebaceous carcinoma of the nasal root) that developed in two of five study patients subsequent to treatment with intralesional interferon alfa-2b for in situ squamous cell carcinoma.
Report of Cases.—Case 1.—
In May 1989, a 59-year-old white man was enrolled in an interferon alfa-2b (Schering Corp, Kenilworth, NJ) protocol for a primary 2.2 × 1.4-cm squamous cell carcinoma in situ of the left upper arm. After an informed consent was obtained, the patient received 1.5 × 106 IU of intralesional interferon triweekly for 3 consecutive weeks. There
Wagner RF, Sanchez RL. Presentation of Sebaceous Carcinoma and Dermatofibrosarcoma Protuberans Subsequent to Intralesional Interferon Alfa-2b for the Treatment of In Situ Squamous Cell Carcinoma. Arch Dermatol. 1991;127(2):272. doi:10.1001/archderm.1991.01680020144030
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: